HTHT News and Press, H World Group Limited From 05/31/22

The following slide deck was published by Huazhu Group Limited in conjunction with their 2022 Q1 earnings call. For further details see: Huazhu Group Limited 2022 Q1 - Results - Earnings Call Presentation

Huazhu press release (NASDAQ:HTHT): Q1 GAAP EPS of -$0.33 beats by $0.02. Revenue of $423M (+15.2% Y/Y) beats by $35.22M. A total of 7,988 hotels or 764,859 hotel rooms in operation as of March 31, 2022. Guidance: In the second quarter of 2022, Huazhu expects revenue to decline 2% to 6% ...

A total of 7,988 hotels or 764,859 hotel rooms in operation as of March 31, 2022. Hotel turnover 1 increased 16.4% year-over-year to RMB9.5 billion for the first quarter of 2022. Excluding Steigenberger Hotels AG and its subsidiaries (“DH”, or “Legac...

Huazhu (NASDAQ:HTHT) is scheduled to announce Q1 earnings results on Tuesday, May 31st, before market open. The consensus EPS Estimate is -$0.38 (-72.7% Y/Y) and the consensus Revenue Estimate is $387.78M (+9.2% Y/Y). Over the last 2 years, HTHT has beaten EPS estimates 50% of the time and ha...

SHANGHAI, China, May 17, 2022 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ: HTHT and HKEX: 1179) (“Huazhu”, “we” or “our”) a world-leading hotel group, today announced that it will schedule to release its unaudited financial results for the firs...

In its prelim Q1 hotel operations, Huazhu (NASDAQ:HTHT) indicates that in its Legacy-Huazhu business, RevPAR recovery in the first two months of 2022 was on track. Steigenberger Hotels AG and its subsidiaries  have been experiencing continuous RevPAR recovery since Germany...

SHANGHAI, China, April 28, 2022 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ: HTHT and HKEX: 1179) (“Huazhu”, “we” or “our”), a world-leading hotel group, today announced preliminary results for hotel operations in the first quarter (“Q1 ...

Biodesix (BDSX) +53%. Actinium Pharmaceuticals ATNM +44% on agreement with Immedica Pharma for conditioning agent. BioCardia BCDA +34% after FDA nod to begin trial of BCDA-04 in COVID patients. Aeglea BioTherapeutics AGLE +19% on filing seeking FDA approval of pe...

Shares of Huazhu Group Limited (NASDAQ:HTHT) traded at a new 52-week high today of $177.20. Approximately 62 million shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares. There is potential upside of 7.0% for shares of Huazhu Group Limited based ...

The following slide deck was published by Huazhu Group Limited in conjunction with their 2021 Q4 earnings call. For further details see: Huazhu Group Limited 2021 Q4 - Results - Earnings Call Presentation